WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014179446) MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/179446    International Application No.:    PCT/US2014/036137
Publication Date: 06.11.2014 International Filing Date: 30.04.2014
IPC:
C12N 15/11 (2006.01), C12N 15/113 (2010.01), A61K 31/7125 (2006.01)
Applicants: REGULUS THERAPEUTICS INC. [US/US]; 3545 John Hopkins Court, Suite 210 San Diego, CA 92121 (US)
Inventors: BHAT, Balkrishen; (US).
HOGAN, Daniel; (US)
Agent: SCARR, Rebecca, B.; McNeill Baur PLLC 125 Cambridge Park Drive, Suite 301 Cambridge, MA 02140 (US)
Priority Data:
61/818,432 01.05.2013 US
61/822,112 10.05.2013 US
61/839,550 26.06.2013 US
61/895,784 25.10.2013 US
61/898,704 01.11.2013 US
61/927,897 15.01.2014 US
Title (EN) MICRORNA COMPOUNDS AND METHODS FOR MODULATING MIR-122
(FR) COMPOSÉS MICROARN ET PROCÉDÉS PERMETTANT LA MODULATION DE L'ACTIVITÉ DE MIR-122
Abstract: front page image
(EN)Described herein are compositions and methods for the inhibition of miR-122 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-122 activity. The compounds may comprise conjugates to facilitate delivery to the liver. The compositions may be administered to subjects infected with hepatitis C virus, as a treatment for hepatitis C virus and related conditions.
(FR)La présente invention concerne des compositions et des procédés pour l'inhibition de l'activité de miR-122. Les compositions présentent certaines modifications de nucléoside qui fournissent des inhibiteurs puissants de l'activité de miR-122. Les composés peuvent comprendre des conjugués pour faciliter l'administration au foie. Les compositions peuvent être administrées à des sujets infectés par le virus de l'hépatite C comme traitement du virus de l'hépatite C et d'états associés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)